PSTV stock forecast
🧾 Current Basics (June 2025)
| Metric | Value |
|---|---|
| Market Cap | $3–7 million (valueresearchonline.com) |
| P/E Ratio (TTM) | N/A (negative earnings) |
| Return on Equity | –5.2% |
| Price-to-Book (P/B) | 3.8× |
PSTV is a clinical-stage pharmaceutical company that focuses on radiotherapeutics for cancer. It has a small market value, big losses, and little revenue (around $5 million TTM), but a high P/B, which shows that investors are hopeful about future advances ([simplywall.st][2]).
🔮 PSTV Stock Predictions
PSTV stock forecast 2025
Positive Phase 2 trial results for GBM (glioblastoma) or liver cancer, such as REYOBIQ or Rhenium-188 NanoLiposome, might be a big reason for the rise. Grants or partnerships might provide you more time to pay off your debts.
2025 Goal: $1.00
PSTV stock forecast 2026
If Phase 2 trials keep showing safety and early effectiveness, PSTV may go on to late-stage investigations or announce a strategic partnership, which would make it more visible.
Target for 2026: $2.50
PSTV stock forecast 2027
Moving on to Phase 3 and getting more signs (such leptomeningeal metastases) makes the product more appealing to businesses. There may be talks about licensing.
2027 Goal: $5.00
PSTV stock forecast 2028
More assets, including the pediatric brain cancer Rhenium study, may go into Phase 2, which would make the pipeline bigger. First licensing negotiations might lead to payouts up front.
Goal for 2028: $8.00
PSTV stock forecast 2029
Starting important studies and working with regulators starts big milestone payments and lays the ground for approval intent.
Goal for 2029: $12.00
PSTV stock forecast 2030
Positive process 3 findings move PSTV into the regulatory filing process, and collaborations make the distribution plan stronger.
Goal for 2030: $18.00
PSTV stock forecast 2031
First product approval (like REYOBIQ) brings in money. The firm moves from the pre-revenue stage to the commercial stage with its first sales.
2031 Goal: $25.00
PSTV stock forecast 2032
Revenue from product launches starts to rise, recurring income from pipelines and services starts, and CAGR growth becomes clear.
2032 Goal: $35.00
PSTV stock forecast 2033
Multiple indication releases and follow-up studies increase the size of the addressable market, which raises value multiples.
2033 Target: $50.00
PSTV stock forecast 2034
Growth into international markets, more cancer assets, and consistent improvements in margins.
2034 Goal: $70.00
PSTV stock forecast 2035
Recurring royalty and license revenue; marketing reach raises EBITDA.
2035 Goal: $90.00
PSTV stock forecast 2036
The pipeline is becoming older, with the second product approaching Phase 3 and the first medicine becoming a potential block-buster.
2036 Goal: $120.00
PSTV stock forecast 2037
Launch of the second treatment, which will help diversify the income basis. PSR changes to a platform with several products.
2037 Target: $160.00
PSTV stock forecast 2038
Strong sales growth and rising profits; operational leverage increases free cash flow.
2038 Goal: $200.00
PSTV stock forecast 2039
A stable biotech company that has been growing at a double-digit rate for a long time and is moving into related cancer sectors.
Goal for 2039: $250.00
PSTV stock forecast 2040
Platform grows into a midsize cancer company with many authorized treatments and a return on equity of more than 10%.
Goal for 2040: $300.00
📈 Table of Yearly Price Targets
| Year | Target (USD) |
|---|---|
| 2025 | 1.00 |
| 2026 | 2.50 |
| 2027 | 5.00 |
| 2028 | 8.00 |
| 2029 | 12.00 |
| 2030 | 18.00 |
| 2031 | 25.00 |
| 2032 | 35.00 |
| 2033 | 50.00 |
| 2034 | 70.00 |
| 2035 | 90.00 |
| 2036 | 120.00 |
| 2037 | 160.00 |
| 2038 | 200.00 |
| 2039 | 250.00 |
| 2040 | 300.00 |
🚀 Things that help growth
- Results of clinical trials—Phase 2/3 results are important markers.
- Broad pipeline development, which includes uses for children and the central nervous system.
- Licensing and grants that free up non-dilutive capital.
- First product commercialization and setting up the commercial engine.
- “Operational leverage,” which means moving from spending on R&D to making more money.
- Valuation expansion—from micro-cap to biotech mid-cap if the approval goes well.
⚠️ Risks and Things to Think About
- High “clinical risk”: failures might lead to big losses.
- If you don’t have enough cash, you need to either dilute or get a loan.
- Delays in regulations might make investors less confident.
- Biotech valuations are unstable; prices are likely to change as trial news comes out.
- Execution risk while scaling up and selling.
📝 Final Thoughts
Plus Therapeutics (PSTV) is a biotech company that is in the trial stage and has a lot of risks and rewards. It may go from less than $1 to more than $20 by 2031 if it gets good clinical evidence and makes headway with regulators. Trial results, alliances, and execution will determine long-term success. By 2040, the company might become a mid-cap oncology player. But there are still big clinical and financial dangers.